Two randomized trials in China find that intra-arterial thrombolysis with urokinase or tenecteplase does not significantly ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

the absolute excess risk of stroke in patients older than age 75 years receiving thrombolytic treatment was <1%, and there was no age-associated excess in the risk of other major bleeding ...

It estimated that 20% of stroke patients could benefit from thrombolysis, a drug that breaks down a clot and returns blood supply to the brain, which should be administered within four and a half ...

Clinuvel Pharmaceuticals (ASX:CUV) has reported encouraging preliminary results from its second study of afamelanotide in ...

A new meta-analysis examines the effects of dual antiplatelet therapy after thrombolysis in minor stroke patients. Findings ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness ...

Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

Tenecteplase thus officially joins the other stroke thrombolytic approved stateside, alteplase (Activase), which is also marketed by Genentech. Notably, off-label tenecteplase had already become ...

Acute ischemic stroke, which occurs due to a blockage in cerebral blood flow, requires prompt intervention with thrombolytic ...

Hyderabad: Apollo Hospitals organised the STAT-2025 Conference on Stroke Thrombolysis and Thrombectomy with leading ...